|
- Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market.
- The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported by joint marketing based on deep ADC expertise.
SEOUL, South Korea, Oct. 30, 2025 /PRNewswire/ -- LOTTE BIOLOGICS (CEO James Park) and SK pharmteco (CEO Joerg Ahlgrimm) announced that they have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the global antibody-drug conjugate (ADC) market.
Through this collaboration, the two companies will jointly investigate providing integrated, one-stop CDMO services to global clients, offering differentiated ADC solutions that span from development to commercial manufacturing.
LOTTE BIOLOGICS will utilize its cGMP manufacturing capabilities and global quality competitiveness at its Syracuse Bio Campus in the U.S. to deliver high-quality bioconjugation and drug substance manufacturing services.
Meanwhile, SK pharmteco will be responsible for linker–payload development and manufacturing within the chemical-synthesis portion of the process, complementing LOTTE BIOLOGICS' bioconjugation and drug-substance manufacturing.
By combining technical expertise and global networks, the companies aim to create a fully integrated CDMO platform that minimizes development-to-manufacturing gaps, offers customized solutions for clients, and strengthens competitiveness in the rapidly expanding ADC sector.
They also plan to jointly pursue global marketing and client engagement to expand their customer base across key markets.
The partnership also aligns with the ongoing global trend toward supply chain reshoring, as each company possess advanced manufacturing infrastructures in both the U.S. and Europe.
James Park, CEO of LOTTE BIOLOGICS, stated, "This collaboration marks a meaningful milestone, as two leading Korean biopharma join forces on the global stage. By combining our strengths in advanced modalities such as ADCs, we will reinforce Korea's biopharmaceutical leadership and accelerate our growth in the global market."
Joerg Ahlgrimm, CEO of SK pharmteco, added, "This strategic partnership will supercharge the development of next-generation therapeutics, positioning both companies to deliver significantly greater value and accelerate the delivery of innovative new medicines to patients around the world."
About LOTTE BIOLOGICS
Headquartered in Seoul, South Korea, LOTTE BIOLOGICS was founded in 2022 with a mission to deliver therapies that contribute to a healthier world. At the Syracuse Bio Campus in New York, LOTTE BIOLOGICS provides high-quality GMP manufacturing services for drug substances. LOTTE BIOLOGICS is also advancing into a new area of expertise with Antibody-Drug Conjugates (ADCs) conjugation services. With over $100 million invested in ADC modalities, including both drug substance and conjugation capabilities on-site, we offer a seamless, end-to-end service from drug substance manufacturing to conjugation. Looking ahead, LOTTE BIOLOGICS is constructing three advanced bio plants in Songdo, South Korea. With construction of the first plant already underway and expected to be operational by 2027.
About SK pharmteco
SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea's second-largest conglomerate.
- Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market.
- The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported by joint marketing based on deep ADC expertise.
SEOUL, South Korea, Oct. 30, 2025 /PRNewswire/ -- LOTTE BIOLOGICS (CEO James Park) and SK pharmteco (CEO Joerg Ahlgrimm) announced that they have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the global antibody-drug conjugate (ADC) market.
Through this collaboration, the two companies will jointly investigate providing integrated, one-stop CDMO services to global clients, offering differentiated ADC solutions that span from development to commercial manufacturing.
LOTTE BIOLOGICS will utilize its cGMP manufacturing capabilities and global quality competitiveness at its Syracuse Bio Campus in the U.S. to deliver high-quality bioconjugation and drug substance manufacturing services.
Meanwhile, SK pharmteco will be responsible for linker–payload development and manufacturing within the chemical-synthesis portion of the process, complementing LOTTE BIOLOGICS' bioconjugation and drug-substance manufacturing.
By combining technical expertise and global networks, the companies aim to create a fully integrated CDMO platform that minimizes development-to-manufacturing gaps, offers customized solutions for clients, and strengthens competitiveness in the rapidly expanding ADC sector.
They also plan to jointly pursue global marketing and client engagement to expand their customer base across key markets.
The partnership also aligns with the ongoing global trend toward supply chain reshoring, as each company possess advanced manufacturing infrastructures in both the U.S. and Europe.
James Park, CEO of LOTTE BIOLOGICS, stated, "This collaboration marks a meaningful milestone, as two leading Korean biopharma join forces on the global stage. By combining our strengths in advanced modalities such as ADCs, we will reinforce Korea's biopharmaceutical leadership and accelerate our growth in the global market."
Joerg Ahlgrimm, CEO of SK pharmteco, added, "This strategic partnership will supercharge the development of next-generation therapeutics, positioning both companies to deliver significantly greater value and accelerate the delivery of innovative new medicines to patients around the world."
About LOTTE BIOLOGICS
Headquartered in Seoul, South Korea, LOTTE BIOLOGICS was founded in 2022 with a mission to deliver therapies that contribute to a healthier world. At the Syracuse Bio Campus in New York, LOTTE BIOLOGICS provides high-quality GMP manufacturing services for drug substances. LOTTE BIOLOGICS is also advancing into a new area of expertise with Antibody-Drug Conjugates (ADCs) conjugation services. With over $100 million invested in ADC modalities, including both drug substance and conjugation capabilities on-site, we offer a seamless, end-to-end service from drug substance manufacturing to conjugation. Looking ahead, LOTTE BIOLOGICS is constructing three advanced bio plants in Songdo, South Korea. With construction of the first plant already underway and expected to be operational by 2027.
About SK pharmteco
SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea's second-largest conglomerate.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities
|
VICTORIA, Seychelles, Jan. 15, 2026 /PRNewswire/ -- MEXC, the fastest-growing global cryptocurrency exchange, redefining a user-first approach to digital assets through true, zero-fee trading today released its 2025 Annual Report. The document outlines a year of intentional transformation, where MEXC evolved from a high-volume platform into a guardian of market integrity, anchored by its foundational commitment to zero-fee trading.
Against a backdrop of industry volatility and heightened security threats, MEXC delivered robust growth in 2025, with futures and spot trading volumes each surging over 130% year-over-year. The exchange served 40 million users and listed 2,287 high-potential projects through its disciplined, list-first approach, distributing over $42.6 million in user rewards.
This performance was powered by MEXC's foundational zero-fee trading strategy, which enabled users to save 1.1 billion USDT in trading fees — an average saving of 320 USDT per user across more than 3,000 spot and futures trading pairs.
In parallel, MEXC engineered a new standard of verifiable trust, introducing monthly Proof of Reserves audits by Hacken, a $100 million Guardian Fund for user protection, and independent third-party oversight of risk controls.
"MEXC has lowered trading barriers through its 0 fee strategy, delivering a measurable impact of more than one billion dollars in improved capital efficiency for our users," said Vugar Usi, Chief Operating Officer of MEXC. "This is not a promotion. It is the foundation of how we operate. In 2026, we will extend this approach beyond crypto as we move into tokenized equities, commodities, and real-world assets."
This strategic expansion is supported by the launch of the MEXC Fund, a $30 million ecosystem investment initiative, and the reinforcement of zero-fee trading as a permanent structural commitment across an expanding multi-asset platform.
MEXC is moving beyond the traditional exchange model to become a seamless gateway to the tokenized future — where markets are accessed with transparency, efficiency, and unwavering trust.
The full 2025 Annual Report is available here.
To see the key moments that defined this record year in action, watch the MEXC 2025 Recap Video here.
About MEXC
Founded in 2018, MEXC is committed to being "Your Easiest Way to Crypto." Serving over 40 million users across 170+ countries and regions, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.
MEXC Official Website | X | Telegram | How to Sign Up on MEXC
VICTORIA, Seychelles, Jan. 15, 2026 /PRNewswire/ -- MEXC, the fastest-growing global cryptocurrency exchange, redefining a user-first approach to digital assets through true, zero-fee trading today released its 2025 Annual Report. The document outlines a year of intentional transformation, where MEXC evolved from a high-volume platform into a guardian of market integrity, anchored by its foundational commitment to zero-fee trading.
Against a backdrop of industry volatility and heightened security threats, MEXC delivered robust growth in 2025, with futures and spot trading volumes each surging over 130% year-over-year. The exchange served 40 million users and listed 2,287 high-potential projects through its disciplined, list-first approach, distributing over $42.6 million in user rewards.
This performance was powered by MEXC's foundational zero-fee trading strategy, which enabled users to save 1.1 billion USDT in trading fees — an average saving of 320 USDT per user across more than 3,000 spot and futures trading pairs.
In parallel, MEXC engineered a new standard of verifiable trust, introducing monthly Proof of Reserves audits by Hacken, a $100 million Guardian Fund for user protection, and independent third-party oversight of risk controls.
"MEXC has lowered trading barriers through its 0 fee strategy, delivering a measurable impact of more than one billion dollars in improved capital efficiency for our users," said Vugar Usi, Chief Operating Officer of MEXC. "This is not a promotion. It is the foundation of how we operate. In 2026, we will extend this approach beyond crypto as we move into tokenized equities, commodities, and real-world assets."
This strategic expansion is supported by the launch of the MEXC Fund, a $30 million ecosystem investment initiative, and the reinforcement of zero-fee trading as a permanent structural commitment across an expanding multi-asset platform.
MEXC is moving beyond the traditional exchange model to become a seamless gateway to the tokenized future — where markets are accessed with transparency, efficiency, and unwavering trust.
The full 2025 Annual Report is available here.
To see the key moments that defined this record year in action, watch the MEXC 2025 Recap Video here.
About MEXC
Founded in 2018, MEXC is committed to being "Your Easiest Way to Crypto." Serving over 40 million users across 170+ countries and regions, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.
MEXC Official Website | X | Telegram | How to Sign Up on MEXC
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
MEXC 2025 Growth Exceeds 130%, Anchored by $1B+ in User Savings from Zero-Fee Trading
